# BioLife Solutions Inc. (BLFS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $35.25, market value $1.7 billion.

## Valuation
- **P/E (trailing): 35.3×**. BioLife Solutions Inc. trades at 35.3× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 106.8×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 1.38**. A PEG of 1.38 is in the range usually read as fairly priced for its growth.
- **Price / sales: 16.5×**. Each dollar of revenue is priced at 16.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 2.8%**. The inverse of the P/E: 2.8% of the price is earned each year.

## Profitability
- **Operating margin: 2.2%**. 2.2% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -4.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -1.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 0.5%**. Return on all capital, debt included, is 0.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 14.3%**. Each dollar of assets produces 14.3% of profit.

## Growth
- **Revenue growth (1 yr): 28.9%** (3-yr 8.1%/yr, 5-yr 14.9%/yr). Revenue grew 28.9% over the last year, against 14.9% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 77.3%**. Earnings per share rose 77.3%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BioLife Solutions Inc. holds more cash than debt.
- **Altman Z-score: 31.82**. A Z-score of 31.82 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BioLife Solutions Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 36.3%** (YTD 45.8%, 3-mo 32.3%). The shares are up 36.3% over twelve months including dividends.
- **From 52-week high: -7.5%** (97.4% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.26** (volatility 44%). Beta of 1.26 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BLFS · Page: https://foliofundamentals.com/stocks/blfs

Not investment advice.